Literature DB >> 18097236

Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.

Carmen de Mendoza1, Carolina Garrido, Angélica Corral, Natalia Zahonero, Vincent Soriano.   

Abstract

Besides I47A, mutation L76V at the HIV protease gene has recently been proposed to cause lopinavir resistance. This change was present in 37 (2.7%) out of 1376 patients failing protease inhibitor containing regimens. Although 26 (70%) were on lopinavir, most had previously failed other protease inhibitors and carried multiple protease inhibitor resistance mutations. Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097236     DOI: 10.1097/QAD.0b013e3282f4244f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  4 in total

1.  Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Authors:  Thomas P Young; Neil T Parkin; Eric Stawiski; Tami Pilot-Matias; Roger Trinh; Dale J Kempf; Michael Norton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

2.  Both a protective and a deleterious role for the L76V mutation.

Authors:  Alessandra Tartaglia; Annalisa Saracino; Laura Monno; Carmine Tinelli; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2009-04       Impact factor: 5.191

3.  Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes.

Authors:  Charlotte Charpentier; Sidonie Lambert-Niclot; Claudia Alteri; Alexandre Storto; Philippe Flandre; Valentina Svicher; Carlo-Federico Perno; Françoise Brun-Vézinet; Vincent Calvez; Anne-Geneviève Marcelin; Francesca Ceccherini-Silberstein; Diane Descamps
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

4.  Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

Authors:  Jade Ghosn; Constance Delaugerre; Philippe Flandre; Julie Galimand; Isabelle Cohen-Codar; François Raffi; Jean-François Delfraissy; Christine Rouzioux; Marie-Laure Chaix
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.